Multiple myeloma patients had a variable response to mRNA COVID-19 vaccines pointing to the need for antibody testing and precautions for these blood cancer patients after vaccination, according to a study published in Cancer Cell on June 29, 2021.
New York City-based Mount Sinai researchers found that multiple myeloma patients mount variable and sometimes suboptimal responses after receiving either the Pfizer-BioNTech or Moderna COVID-19 vaccines.
Read More
